Home
About
Company Profile
Company Leadership
Technology
Product Pipeline
Intranasal Naloxone
Intranasal Epinephrine
Intranasal drug delivery
Taffix™
News
Contact
Menu
Home
About
Company Profile
Company Leadership
Technology
Product Pipeline
Intranasal Naloxone
Intranasal Epinephrine
Intranasal drug delivery
Taffix™
News
Contact
Intranasal Epinephrine
Intranasal Epinephrine (NS –002)
Medical need and size
Definition: Severe allergic type 1 reaction. Life threatening,
Prevalence: 1.5 % of the US population suffer an event each •( 500,000 cases annually)
Cost of treatment 4 B annually
Mortality rates 1.2 % per episode, 30 % recurrence risk lifetime
Epinephrine IM or IV is the first line treatment.
Market structure
Regulatory requirements : 505 b 2 . Comparator: Epipen ,
Development plan : POC study to start Q 2 2020
Contact us for more information
CLICK HERE